Navigation Links
New Antioxidant Drug Shows Promise Against Diabetes
Date:5/23/2008

But more studies on cardiovascular risks needed, report says

FRIDAY, May 23 (HealthDay News) -- A new antioxidant drug shows benefits in the prevention and treatment of diabetes, but more research on possible cardiovascular risks is needed before it is used widely, a new study indicates.

Preliminary results on the drug, succinobucol, have been presented at medical meetings. The full study is published in the May 24 issue of The Lancet.

"There is more data in the article than in the previous presentation, with greater detail on the prevention of diabetes and glycemic [sugar] control," said study author Dr. Jean-Claude Tardif, director of the research center at the Montreal Heart Institute in Canada.

"There are several interesting findings that include a large reduction of new cases of diabetes and also glycemic control in patients who already have diabetes," Tardif said. "But there needs to be confirmation before it is used widely, because there was no effect on clinical endpoints such as heart attack and stroke."

Some confirmation of the drug's effectiveness is expected from a major trial that is nearing completion, Tardif said. Results of that trial should be published "within the next few months," he said.

Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug taken off the market in the United States in 1995 because of side effects. In addition to its antioxidant effects, succinobucol also reduces inflammation.

The trial reported in The Lancet included 6,144 people, 37 percent of whom had diabetes and all of whom had been hospitalized for a heart attack or the dangerous heart rhythm problem called unstable angina. For two years, half of the participants took succinobucol daily, while the other half took a placebo. All were taking other drugs, such as cholesterol-lowering statins, beta blockers or ACE inhibitors.

Among the participants who did not have diabetes when the study began, 4.2 percent of those not taking succinobucol developed the disease, compared to 1.64 percent of those taking the drug, a 64 percent risk reduction. For those with diabetes, taking succinobucol provided better blood sugar control than not taking the drug.

Atrial fibrillation, a dangerous heartbeat abnormality, was twice as likely to develop during the trial in those taking succinobucol. There was no difference in the incidence of death, cardiac arrest, heart attack, stroke or other cardiovascular endpoints between those taking or not taking the drug.

"The study results need confirmation before it is used widely, because there was no effect on those clinical endpoints," Tardif said. "But that is true of all the drugs now used in diabetes. There is no evidence that they reduce heart attacks and strokes."

The chief side effect of the drug was diarrhea, reported by 23 percent of those taking it. One in seven of those reporting diarrhea stopped taking succinobucol.

More information

Currently available drugs for diabetes are described by the American Diabetes Association.



SOURCES: Jean-Claude Tardif, M.D., director, Montreal Heart Institute Research Center, Canada; May 23, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Antioxidant Supplements May Raise Womens Skin Cancer Risk
3. New research into plant colors sheds light on antioxidants
4. Antioxidants do not prevent degenerative eye disease
5. Major ORAC Differences Among Top Antioxidant Beverages
6. Grape Consumption Improves Antioxidant Capacity in Humans
7. Snapples New Antioxidant Water and LYTeWater Take Hydration to the Next Level
8. Citrus juice, vitamin C give staying power to green tea antioxidants
9. Natural Antioxidants Help Reduce Oxidative Stress in Diabetes Treatment
10. New Research Confirms Wild Blueberry Antioxidant Power
11. Citrus Juice Gives Boost to Green Tea Antioxidants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Antioxidant Drug Shows Promise Against Diabetes
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology: